Published in Lancet Neurol on June 29, 2015
Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol (2015) 1.55
Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain (2016) 1.51
Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimers Dement (Amst) (2017) 0.76
Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. Neurology (2016) 0.75
Biomarkers for Alzheimer's disease: a controversial topic. Lancet Neurol (2015) 0.75
Can MRI T1 be used to detect early changes in 5xFAD Alzheimer's mouse brain? MAGMA (2016) 0.75
Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement (Amst) (2017) 0.75
Predicting regional pattern of longitudinal beta-amyloid accumulation by baseline positron emission tomography. J Nucl Med (2016) 0.75
Polyphenols for the prevention and treatment of dementia diseases. Neural Regen Res (2015) 0.75
Learning to classify neural activity from a mouse model of Alzheimer's disease amyloidosis versus controls. Alzheimers Dement (Amst) (2016) 0.75
Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome. Neurobiol Aging (2017) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage (2011) 6.60
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology (1994) 5.81
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol (2006) 4.19
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Testing the right target and right drug at the right stage. Sci Transl Med (2011) 3.55
2014 Alzheimer's disease facts and figures. Alzheimers Dement (2014) 3.45
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65
Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology (2000) 2.64
Biomarker modeling of Alzheimer's disease. Neuron (2013) 2.51
Brain β-amyloid load approaches a plateau. Neurology (2013) 2.50
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med (2006) 2.17
Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci (2009) 1.89
The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging (2010) 1.63
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology (2014) 1.47
High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol (2009) 1.45
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol (2012) 1.25
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol (2015) 1.23
Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage (2013) 1.17
Combining atlas-based parcellation of regional brain data acquired across scanners at 1.5 T and 3.0 T field strengths. Neuroimage (2012) 0.92
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement (2014) 1.14
Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. J Alzheimers Dis (2015) 1.04
Association of plasma and cortical amyloid beta is modulated by APOE ε4 status. Alzheimers Dement (2013) 0.89
Amyloid-β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. J Alzheimers Dis (2015) 0.85
Magnetic resonance imaging predictors of treatment response in late-life depression. J Geriatr Psychiatry Neurol (2013) 0.84
The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. Alzheimers Dement (2015) 0.84
Comparison of qualitative and quantitative imaging characteristics of [(11)C]PiB and [(18)F]flutemetamol in normal control and Alzheimer's subjects. Neuroimage Clin (2015) 0.82
Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement (2016) 0.82
Trajectories of peripheral interleukin-6, structure of the hippocampus, and cognitive impairment over 14 years in older adults. Neurobiol Aging (2015) 0.80
Voxel Level Survival Analysis of Grey Matter Volume and Incident Mild Cognitive Impairment or Alzheimer's Disease. J Alzheimers Dis (2015) 0.78
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement (2015) 0.78
Fetuin-A and risk of coronary heart disease: A Mendelian randomization analysis and a pooled analysis of AHSG genetic variants in 7 prospective studies. Atherosclerosis (2015) 0.78
Sparse Clustering with Resampling for Subject Classification in PET Amyloid Imaging Studies. IEEE Nucl Sci Symp Conf Rec (1997) (2011) 0.78
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol (2017) 0.77
Cardiovascular and autonomic reactivity to psychological stress: Neurophysiological substrates and links to cardiovascular disease. Auton Neurosci (2017) 0.76
MRS in early and presymptomatic carriers of a novel octapeptide repeat insertion in the prion protein gene. J Neuroimaging (2012) 0.75
Longitudinal Relationships between Caloric Expenditure and Gray Matter in the Cardiovascular Health Study. J Alzheimers Dis (2016) 0.75
Association analysis of 23 susceptibility loci with risk of dementia in a Pakistani population. Psychiatry Res (2014) 0.75
In Memoriam: Robert M. Stern. Neurogastroenterol Motil (2020) 0.75
Associations of body composition with incident dementia in older adults: Cardiovascular Health Study-Cognition Study. Alzheimers Dement (2020) 0.75
Long-term changes in time spent walking and subsequent cognitive and structural brain changes in older adults. Neurobiol Aging (2017) 0.75